deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00366444

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

Sponsor: Xanodyne Pharmaceuticals

Conditions Pain, Postoperative
Interventions Placebo diclofenac potassium (XP21L)
Updated 5 times since 2017 Last updated: Apr 12, 2011 Started: Aug 31, 2006 Primary completion: Oct 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Pain, Postoperative and is currently completed. Xanodyne Pharmaceuticals leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Xanodyne Pharmaceuticals
Data source: Xanodyne Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations